Table 3 Change in functional, haemodynamic, and cardiac parameters from baseline to 6Â month follow up assessment
| Â | Groups | P-values | |||||
|---|---|---|---|---|---|---|---|
|  | Control (n = 20) | Repair (n = 30) | Replace (n = 22) | All groups | Control vs repair | Control vs replace | Repair vs replace |
Systolic BP (mmHg) | − 0.2 ± 21 | + 0.8 ± 11 | + 0.1 ± 12 | 0.952 |  |  |  |
Diastolic BP (mmHg) | + 0.5 ± 14 | + 2.8 ± 10 | + 0.1 ± 9.2 | 0.510 |  |  |  |
Heart rate (bpm) | − 3.0 ± 10 | + 3.1 ± 21 | − 1.8 ± 12 | 0.359 |  |  |  |
6MWT distance (m) | + 0.1 ± 55 | + 57 ± 54 | + 64 ± 76 | 0.002 | 0.007 | 0.005 | 1 |
NYHA functional class | 0.15 ± 0.4 | − 0.8 ± 0.7 | − 1.1 ± 0.7 | < 0.001 | < 0.001 | < 0.001 | 0.281 |
LVEDVi (ml/m2) | − 1.3 ± 12 | − 29 ± 21 | − 37 ± 22 | < 0.001 | < 0.001 | < 0.001 | 0.584 |
LVESVi (ml/m2) | − 1.7 ± 7.4 | − 4.0 ± 16 | − 8.3 ± 18 | 0.360 |  |  |  |
LVSVi (ml/m2) | − 0.1 ± 8.4 | − 25 ± 15 | − 28 ± 13 | < 0.001 | < 0.001 | < 0.001 | 1 |
LVEF (%) | + 0.4 ± 3.9 | − 8.7 ± 8.9 | − 8.8 ± 9.0 | < 0.001 | < 0.001 | 0.001 | 1 |
Effective forward-LVEF (%) | + 0.2 ± 3.9 | + 8.8 ± 8.3 | + 14 ± 8.7 | < 0.001 | < 0.001 | < 0.001 | 0.060 |
LVMi (g/m2) | + 0.3 ± 4.3 | − 3.8 ± 10 | − 3.7 ± 11 | 0.256 |  |  |  |
LA volume indexed (ml/m2) | + 1.2 ± 19 | − 27 ± 30 | − 39 ± 26 | < 0.001 | 0.002 | < 0.001 | 0.545 |
MR Rvol (ml) | − 0.1 ± 12 | − 47 ± 21 | − 62 ± 27 | < 0.001 | < 0.001 | < 0.001 | 0.064 |
MR RF (%) | + 0.4 ± 7.0 | − 29 ± 11 | − 40 ± 14 | < 0.001 | < 0.001 | < 0.001 | 0.002 |
RVEDVi (ml/m2) | − 0.9 ± 5.5 | − 5.0 ± 16 | − 7.1 ± 20 | 0.436 |  |  |  |
RVESVi (ml/m2) | + 0.6 ± 5.5 | − 3.5 ± 14 | − 9.1 ± 17 | 0.051 |  |  |  |
RVSVi (ml/m2) | − 3.3 ± 9.0 | − 1.5 ± 11 | + 1.9 ± 10 | 0.487 |  |  |  |
RVEF (%) | − 0.8 ± 4.0 | + 1.0 ± 9.5 | + 4.9 ± 7.9 | 0.067 |  |  |  |
TR Rvol (ml) | + 0.5 ± 21 | − 5.1 ± 17 | − 2.9 ± 13 | 0.493 |  |  |  |
TR RF (%) | + 2.1 ± 21 | − 6.6 ± 20 | − 4.5 ± 14 | 0.614 |  |  |  |
RAAi (cm2/m2) | 0.0 ± 2.5 | 0.0 ± 2.9 | − 1.1 ± 3.9 | 0.568 |  |  |  |